2014 Fiscal Year Final Research Report
Research and comparison of new therapeutic agents for fatty acid metabolism disorders
| Project/Area Number |
25860863
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Shimane University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | 脂肪酸代謝異常症 / β酸化 / in vitro probe assay / レスベラトロール / ベザフィブレート / CPT2欠損症 / VLCAD欠損症 |
|---|
| Outline of Final Research Achievements |
As a new treatment for a fatty acid metabolism disorders CPT2 deficiency and VLCAD deficiency, that the β-oxidation damage can be improved it has been revealed by bezafibrate (BEZ) and resveratrol (RVL). These drugs are administered to the same cell, to compare the β-oxidation ability with in vitro probe assay.
CPT2 deficiency, VLCAD deficiency rise of C16, ie there is a long-chain fatty acid metabolism disorder, by the administration of RVL, was hoping that the C16 is reduced. However, it has been administered RVL at various concentrations in the blood concentration of historical literature reference even further increase in C16 in either, it resulted to be considered worsening That want β-oxidation.
|
| Free Research Field |
先天代謝異常症
|
